San Diego – October 27, 2026 -- Atrium Therapeutics (Nasdaq: RNA) has dosed the first patient in Corventis, a Phase 1/2 trial of ATR 1072 in PRKAG2 syndrome, and expects initial proof-of-concept data in the second half of 2027.